A successful scientific trial has pushed Comvita's share price to a five-year high and suggests the company's olive-leaf extract may help prevent a form of diabetes in overweight, middle-aged men.
The NZX-listed health company well known for its honey products had its olive-leaf extract examined by the Liggins Institute at the University of Auckland.
The institute found use of the extract improved insulin release and sensitivity in the middle-aged, overweight men who participated in the trial and were at risk of developing type 2 diabetes.
According to Diabetes New Zealand, this variant of the metabolic disorder is when someone's production of insulin slows ortheir body is resistant to the hormone.
Advertisement
Advertise with NZME.A lack of insulin leads to excess glucose in the blood, which can cause kidney disease and other health problems.
Comvita chief executive Brett Hewlett said type-2 diabetes was an "epidemic" and olive-leaf extract therefore had a global market.
"Diabetes is bit of a global epidemic right now. It's estimated around 4 per cent of the New Zealand population suffers from diabetes and in the US it's 8 per cent."
Despite the trial results, Hewlett said the extract was by no means a "silver bullet" for the disease.
"This isn't a cure for diabetes," he said.
"Potentially this is just one of many weapons that healthcare professionals can use and offer up as a potential preventer of diabetes."
Shares in Comvita, which is well known for its honey products climbed to a five-year high following the release of the trial results, and closed up 10c yesterday at $3.80.
The trial involved 45 men who were classed as overweight based on their body mass index. The results had yet to be peer-reviewed but had been submitted for publication in an international medical journal, Comvita said.
Advertisement
Advertise with NZME."We're already thinking about potential new research products and follow-up research projects we can do," Hewlett said, "and those might lead to other new products or developments."
